Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  darbepoetin alfa
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 33 for your search:
Start Over
The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2612-2277, NCT00122720
An Observational Study of Blood Management Techniques in Oncology Surgical Treatment
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003460, EPOSUR4001, NCT00264095
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
Phase: Phase IV
Type: Health services research, Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR002455, EPOCAN4015, NCT00264108
Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 04/Q1907/94, NCT00234143
Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer
Phase: Phase III, Phase II
Type: Supportive care
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: 2005-005658-37, LM: 2612-3148, Ethical: 20060074, Data Protection: 2005-41-6015, NCT00381836
Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 16 to 69
Sponsor: Other
Protocol IDs: TJE0301, NCT00557817
Anemia in Patients With a Non-Myeloid Malignancy
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20010101, UCLA-0201098, NCI-G02-2112, AMGEN-200101101, NCT00046982, NCT00038064
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000333213, P30CA016042, UCLA-0306021, AMGEN-20030125, NCT00070382
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20010145, NCT00119613
R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 66 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: LNH03-6B, NCT00144755
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040156, NCT00135317
A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 20 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: KRN321-SC/05-A54, NCT00344409
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000593480, P30CA015083, MC04CC, NCI-2009-01226, 1713-05, MAYO-MC04CC, NCT00661999
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20010103, UCLA-0403046-01, AMGEN-20010103, NCT00091858
Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20090160, NCT01362140
A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HEMMDS0001, 13536, NCT00230321
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: 02-090, MSKCC-02090, NCT00058422
Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000350089, U10CA031946, CALGB-30303, NCT00077311
Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia?
Phase: Phase II
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 01/155A, NCT00039884
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
Phase: Phase II
Type: Supportive care
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20030204, NCT00095277
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040262, NCT00144131
Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: jth_004, NCT00204633
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040232, NCT00239239
Start Over